Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000919 · ClinicalTrials.gov registry record · NA

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

A NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
900
Enrollment target
20
Study locations

NCT00000919 is a NA study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 900 participants, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (103% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000919, a NA study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
900 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the effectiveness of various combinations of anti-HIV drugs in HIV-positive men and women. Patients receive specific combinations of 3 or 4 of the following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV), lamivudine (3TC), or zidovudine (ZDV). Anti-HIV therapy is effective in preventing the spread of HIV in the body. However, patients often experience unpleasant side effects and have difficulties following the dosing schedule. This study looks for combinations of anti-HIV drugs ("cocktails") which will be the most effective with the fewest problems.

Conditions Studied

HIV Infections

Interventions

  • DRUG Hydroxyurea
  • DRUG Ritonavir
  • DRUG Indinavir sulfate
  • DRUG Lamivudine/Zidovudine
  • DRUG Abacavir sulfate

Study Locations (20)

California

  • Univ of Southern California / LA County USC Med Ctr - Los Angeles
  • UCLA CARE Ctr - Los Angeles
  • Willow Clinic - Menlo Park
  • Univ of California / San Diego Treatment Ctr - San Diego
  • San Francisco AIDS Clinic / San Francisco Gen Hosp - San Francisco
  • San Francisco Gen Hosp - San Francisco
  • Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium - San Jose
  • Marin County Specialty Clinic - San Rafael
  • San Mateo AIDS Program / Stanford Univ - Stanford
  • Stanford Univ Med Ctr - Stanford
  • Harbor UCLA Med Ctr - Torrance

District of Columbia

  • Georgetown Univ Hosp - Washington D.C.
  • Howard Univ - Washington D.C.

Georgia

  • Emory Univ - Atlanta
  • Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr - Atlanta

Alabama

  • Univ of Alabama at Birmingham - Birmingham

Colorado

  • Univ of Colorado Health Sciences Ctr - Denver

Florida

  • Univ of Miami School of Medicine - Miami

Hawaii

  • Univ of Hawaii - Honolulu

Illinois

  • Northwestern Univ Med School - Chicago

Trial Details

FieldValue
Enrollment Target 900 participants
Est. Completion 2002-11
Phase NA

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00000919

The ClinicalTrials.gov registry entry for NCT00000919 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (103% higher). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Hydroxyurea is the first listed.

NCT00000919 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, District of Columbia, Georgia.

Frequently Asked Questions

What is clinical trial NCT00000919 about?

NCT00000919 is a clinical study titled "A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection". The purpose of this study is to compare the effectiveness of various combinations of anti-HIV drugs in HIV-positive men and women. Patients receive specific combinations of 3 or 4 of the following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV), lamivudine (3TC), or zido...

What is the current status of trial NCT00000919?

This trial is currently completed. It is a NA study. The enrollment target is 900 participants. Estimated completion is 2002-11.

What conditions does trial NCT00000919 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000919?

The interventions under investigation include: Hydroxyurea (DRUG), Ritonavir (DRUG), Indinavir sulfate (DRUG), Lamivudine/Zidovudine (DRUG), Abacavir sulfate (DRUG).

Who is sponsoring clinical trial NCT00000919?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000919 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.